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Abstract
Paraneoplastic disorders are rare multiorgan diseases associated with hematological
malignancies such as chronic lymphocytic leukemia (CLL). Some of these paraneoplasms
manifest as cutaneous lesions, appearing as a simple rash, ulcers or skin thickening. The
pathogenesis for this process has been described as development of certain autoimmune
reactions against cell wall antigens and proteins. An example is paraneoplastic pemphigus
(PNP) which manifests as cutaneous bullae. Bullae may occur anytime during the course of the
malignancy i.e. acute phase or remission. Diagnosis involves evaluation of clinical findings,
serology and presence of characteristic histological findings. Its pathogenesis is described as
development of auto-antibodies against cell junctional and basement membrane proteins.
Presence of paraneoplasms has been associated with poorer prognosis and increased mortality
in hematological malignancies including CLL. Currently, there are established indications for
the treatment of CLL; however, presence of paraneoplasms as an indication for treatment is
unclear. Patients with paraneoplasms who underwent expeditious treatment have exhibited
better clinical outcomes. Herein we describe a case of a CLL patient in remission presenting
with PNP and its response to treatment.
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Introduction
Chronic lymphocytic leukemia (CLL) is a hematological malignancy of clonal B cells
characterized by the accumulation of monoclonal B cell lymphocytes in the blood. CLL is the
most common of the adult leukemias in the western world [1, 2]. It constitutes about 25 to 30%
of all leukemias in the United States with more than 17,000 new cases reported every year,
mostly men with estimated median age of 70 [2, 3]. If treated, CLL has a five-year survival rate
of over 76% [4]. However, not all CLL is treated immediately unless they meet the criteria for
the indications to treat [5].
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Paraneoplasms are rare multi-organ diseases associated with neoplasia mainly of
lymphoproliferative origin such as leukemia, lymphoma, Castleman’s disease, etc. They are
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characterized by autoantibodies-antigen mediated manifestations. These paraneoplasms may
present as cutaneous lesions, commonly referred to as cutaneous variant paraneoplasms.
Examples include bullous pemphigoid, erythema multiforme, graft versus host disease, lichen
planus and eosinophilic dermatoses of hematological malignancy among others [6]. The
diagnosis of these paraneoplasms depends on the correlation between clinical manifestations
and histopathological findings. Paraneoplastic pemphigus (PNP) is a cutaneous variant of CLL.
Its pathogenesis is similar to that of regular cutaneous pemphigoids which involves formation
of autoantibodies against proteins such as desmoglein-1, desmoglein-3, desmocollin
desmoplakin-1, desmoplakin II which are responsible for formation of cell junctions [2, 6].
Diagnosis is primarily made through skin biopsy and direct immunofluorescence showing
deposition of IgG at the epithelial basement membrane. In these patients,
immunohistochemical stain demonstrates expression of CD-20 and CD-23 which are seen in
CLL [7]. Many case reports have shown that patients with PNP have poor prognosis and a high
mortality rate reported to be upwards of 75-90% with an average survival of less than one year
[5]. Steroids are the recommended first line treatment with a few reports showing response to
immunosuppressants such as cyclophosphamide, mycophenolate mofetil, azathioprine, IgG
and chemotherapy such as ibrutinib [2, 6, 7]. Herein we present a case of a 70-year-old female
with history of CLL in which presentation significant of PNP was indicative of recurrence of
disease.

Case Presentation
We present a 79-year-old female with a long-standing history of CLL diagnosed about 10 years
ago, who had been on the watch and wait protocol as she was clinically in remission.
Collaterally she initially presented to the emergency department (ED) in July of 2014 as a stroke
notification. At that time, she was found to have an acute bilateral ischemic cerebrovascular
accident with hyperleukocytosis of 200 x 109/L, anemia and thrombocytopenia. At that time of
hospitalization, she was also found to have acute myocardial infarction and deep venous
thrombosis of the left popliteal vein for which she was treated with dual anti-platelet therapy
and full dose anticoagulation. Due to altered mental status in setting of multiple acute
pathologies she was intubated for airway protection and admitted to the medical intensive care
unit (MICU) for further management. She underwent a total of four weekly cycles of
hydroxyurea and rituximab which she tolerated well. Subsequently, she was placed on
hydroxyurea. After initial rituximab, she had further treatments for maintenance. By December
2016, it was determined that she was in remission and thus was discontinued on all CLL
treatments and recommended to continue clinic follow-up every three to six months. WBC
after remission was noted to be less than 10 x 109/L. Home medications consisted of enalapril,
sitagliptin, metformin, insulin glargine, atorvastatin and folic acid.
In October 2018, two years after initial ED visit, she presented with a chief complaint of itchy
rash on her upper and lower extremities. Physical exam revealed wheelchair bound elderly
female, with normal cardiopulmonary exam with skin exam revealing multiple blisters and
small bullae on face, neck and forearms with surrounding erythema and desquamation.
Laboratory findings are shown below in Table 1. Peripheral flow cytometry findings were
consistent with a CD5+ B-cell lymphoproliferative disorder (66% of total cells).

2020 Onukogu et al. Cureus 12(5): e8316. DOI 10.7759/cureus.8316

2 of 7

Viral and
Cell Count

Biochemistry

CMP

Autoimmune
Panel

Prior to
treatment with

At CLL
remission

Detection of

1 st cycle of

following

PNP lesions

Rituximab

Rituximab

200

8.70

26.5

Na

20

41.8

30

K

75

50.6

68

Cl

4.5

6.6

2.0

Total Protein

Eosinophils
%

0.4

0.7

0.0

Albumin

Basophils %

0.1

0.3

0.0

T-Bil

RBC x1012/L

4.0

3.45

4.27

ALT

HBG g/dl

10

12.1

12.9

AST

99

155

166

LDH

WCC x109 /L
Neutrophils
%
Lymphocytes
%
Monocytes
%

Platelets
9

x10 /L

144
HIV
mmol/L
4.9
mmol/L

EBV titre

CMV
99
antigenemia
mmol/L
assay
6.4

Nonreactive

0.9

Negative

HSV

Negative

VZV

Negative

HepBsAg

Negative

11 U/L

HCV

Negative

16 U/L

ANA

1:40

183

Kappa free

U/L

light chains

Beta-2-

2.1

Lambda free

Microglobulin

mg/L

light chains

g/dl
4.4
g/dl
0.2
mg/dl

1.60 mg/dl

1.27 mg/dl

BP 180

>100 U

BP 230

<5 U

TABLE 1: Laboratory findings during the course of disease progression.
ALT: Alanine aminotransferase; ANA: Antinuclear antibody; AST: Aspartate aminotransferase; BP: Bullous pemphigoid; CMV:
Cytomegalovirus; EBV: Epstein-Barr virus; HBG: Hemoglobin; HepBsAg: Hepatitis B surface antigen; HCV: Hepatitis C virus; HIV:
Human immunodeficiency virus; RBC: Red blood cell count; T-Bil: Total Bilirubin; WCC: White cell count; VZV: Varicella zoster virus.

Skin biopsy was subsequently performed with direct immunofluorescence which noted
presence of C3 and IgG aligning the roof and floor of induced blisters. Findings were found to
be compatible with pemphigoid family of diseases including bullous pemphigoid and druginduced pemphigoid. The patient was initially treated with 1 mg/kg of prednisone with
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transient resolution of cutaneous lesions for a week. Due to the lack of response to steroid
therapy, we initiated treatment with the Bruton Tyrosine kinase inhibitor ibrutinib and anti-CD
20+ monoclonal antibody rituximab. The patient is currently in treatment phase with good
clinical response which has been shown in Figure 1. The patient continues to follow up in
Hematology/Oncology clinic and with Dermatology.

FIGURE 1: The pemphigus lesions of the neck and forearm
before (1 & 2) and after (3 & 4) treatment. Arrows point to
lesions of interest.

Discussion
Paraneoplastic pemphigus is a rare autoimmune manifestation of hematological malignancies
most commonly lymphoproliferative disorders with some reports indicating an incidence of up
to 25% [8]. Although underreported or under diagnosed, identified cases occurred between fifth
and eighth decades of life [1]. Paraneoplastic pemphigus is a life-threatening mucocutaneous
polymorphic subtype of pemphigus with a variable clinical presentation. Other common
etiologies include chemotherapy with drugs such as ibrutinib, purine analogs, and alkylating
agents. A few cases have been associated with insect bites through proliferation of eosinophilia
by activation of IL4 and IL5 activities [7]. The clinicopathological picture mimics that of
pemphigus vulgaris, pemphigus foliaceus, pemphigoid, erythema multiforme, graft versus host
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disease or lichen planus [9, 10].
The clinical onset of PNP in relation to the underlying hematological malignancy may occur
over three timelines. In about two-thirds of cases PNP precedes the detection of the
malignancy, with some cases diagnosed during active disease or during remission [11]. A
myriad of cases postulate underlying pathogenesis of PNP since its initial discovery. The most
widely accepted theory postulates that the malignant process induces both humoral and cellmediated immunity. The driver mechanism involves the activation of autoantibody production
in response to maladaptive immune function and cross reactivity between antibodies directed
against tumor cells and epithelial antigens [12]. Autoantibodies against desmoplakins,
specifically envoplakin and periplakin, underlie the major antigenic proteins in PNP. These
proteins act as epidermal cell adhesion molecules and anchoring proteins for intermediate
filaments to desmosomes [13-15]. Less common antigenic proteins include desmoglein-3,
desmoplakin-1, desmoplakin II, bullous pemphigoid antigen-1, plectin and protease inhibitor
alpha-2-macroglobulin-like-1 (A2ML1). The presence of AntiCD20+ and AntiCD23+ has been
detected in PNP due to CLL. The cell-mediated immunity involvement is supported by the
detection of CD8+ T lymphocytes, CD56+ and monocytes/macrophages in intraepithelial cell
spaces and the dermo-epidermal junction in biopsy samples of affected patients [16]. Other
components of the cellular inflammatory process include the production of proinflammatory
cytokines such as IL-6, interferon gamma and TNF-alpha which elicit antibody production and
CD8+ T lymphocyte activation [17]. The processes described above promote keratinocyte
acantholysis resulting in intraepidermal and dermo-epidermal blistering.
Clinical presentation is characterized by the presence of polymorphous lesions evidenced by
mucocutaneous papules, pustules, lichenoid plaques, flaccid/tense bullae, desquamative and
psoriasiform lesions [11]. Diagnostic modalities for the detection of PNP include lesion skin
biopsy for light microscopy and direct immunofluorescence microscopy, serum for ELISA and
indirect immunofluorescence. Supportive laboratory tests to diagnose CLL such as complete
blood count /with differential, peripheral blood smear, bone marrow aspirate,
immunophenotyping and genetic analysis are required as well. Due to the variable
histopathological presentation of PNP, a high degree of clinical suspicion with supportive
immunohistological findings is required to arrive at a diagnosis.
There is a paucity of data on the treatment of PNP in patients with CLL. Therapeutic modalities
that have yielded clinical response include the use of oral glucocorticoids, plasmapheresis,
chemotherapy, intravenous immunoglobulins, and myeloablation with anti-CD52+ monoclonal
antibody alemtuzumab [18, 19]. Recent evidence has shown clinical response to the
combination of Bruton Tyrosine kinase inhibitor Ibrutinib and anti-CD 20+ monoclonal
antibody rituximab in patients with CD5+ B-cell chronic lymphocytic leukemia and PNP [20].

Conclusions
Herein we presented a case of a 79-year-old female with history of CLL who presented with
PNP, representing a paraneoplasm. In this case, the skin lesions were identified as PNP and was
an indicator of disease recurrence. As demonstrated cutaneous lesions are a possible
manifestation of paraneoplasms in the setting of CLL. These lesions can occur secondary to
hematological disease, chemotherapy side effects or even insect bites. Thus, diagnostic
differentiation among these lesions is a challenge but is necessary to guide therapy. Indirect
immunofluorescence has been shown to be most specific for diagnostic accuracy. The proposed
pathogenesis involves activation of both humoral and cell-mediated immunities leading to
proliferation of auto antibodies against tumor cell surface and epithelial antigens. Most cases
of PNP have demonstrated good clinical response to steroids, chemotherapy, immunoglobulins
and immunosuppressant depending on the severity and stage of disease. Clinicians should be
aware of PNP and its clinical significance in the setting of CLL.
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